Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Withdrawn × Introns × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 1/2 1

Status

Completed 5 Active not recruiting 4 Unknown 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Cisplatin 17 Carboplatin 11 Radiotherapy 10 Paclitaxel 9 Fluorouracil 8 Rituximab 7 Gemcitabine 7 Capecitabine 5 Vinorelbine 4 Nivolumab 4 Drug Therapy 4 Docetaxel 4 Bevacizumab 4 spartalizumab 3 pertuzumab 3 pembrolizumab 3 Trastuzumab 3 Standard of Care 3 Pemetrexed 3 Oxaliplatin 3 Etoposide 3 Dexamethasone 3 Cyclophosphamide 3 Cetuximab 3 Bendamustine Hydrochloride 3 parsaclisib 2 linrodostat 2 lenvatinib 2 human papillomavirus vaccine, L1 type 16, 18 2 fludarabine phosphate 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01860742 2016-04-05

CASTOR

Jules Bordet Institute

Phase 3 Withdrawn

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡